Stop whining: Insurers and the high price hype of Hepatitis C
from By Jason Poquette
There has been a lot of fuss in the media over the price of the newest treatment options for Hepatitis C, a condition affecting around 3 million Americans. Sovaldi by Gilead costs $84,000 for a 12-week course of therapy. Their competitor Olysio by Janssen comes in around $66,000 for the same 12 weeks. This high price tag has caused many players in the market to moan and cry, particularly the insurance companies who have to come up with ways to pay the bill.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063